Ethris Reports Topline Data from P-I trial of ETH47 for Uncontrollable Asthma
Shots:
- Ethris presented full topline data from P-I trial of ETH47 (nasal) in 40 healthy subjects as a potential treatment for uncontrollable asthma
- Study showed dose-dependent IFNλ production in nasal lining fluid above therapeutic levels & activated antiviral ISG mRNA expression in nasal brush samples, confirming ETH47’s pharmacodynamic activity & MoA. Based on this, Ethris filed a CTA to initiate a P-IIa trial for asthma pts in Q2’25 to assess its efficacy in reducing lower respiratory symptoms incl. rhinovirus
- ETH47 (mRNA) nasal spray developed by using Ethris’ SNIM RNA & SNaP LNP platform, triggers a local cascade of antiviral interferon-stimulated genes and provide relief in asthmatic symptoms
Ref: Businesswire | Image: Ethris
Related News:- Roche Reports Topline Data from P-III (INAVO120) Trial of Itovebi (Inavolisib) to Treat HR-Positive Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
